Biodegradable Stents

Biodegradable Stents Market Outlook

The global biodegradable stents market is poised for substantial growth, with a projected market size of approximately USD 3.2 billion by 2035, expanding at a CAGR of around 12.5% from 2025 to 2035. The accelerating prevalence of cardiovascular diseases and the rise in surgical procedures are driving the demand for biodegradable stents, which are favored for their superior biocompatibility and reduced long-term complications compared to traditional metal stents. Moreover, the increasing adoption of minimally invasive procedures, coupled with advancements in stent technology and materials, is contributing significantly to the growth of this market. The growing awareness regarding the benefits of biodegradable stents over conventional solutions is further compelling healthcare professionals to explore these innovative treatments. As healthcare systems globally emphasize patient outcomes and safety, the biodegradable stents market is expected to gain significant traction.

Growth Factor of the Market

One of the primary growth factors for the biodegradable stents market is the rising incidence of cardiovascular diseases, which necessitates effective treatment options that minimize long-term health complications. The aging population is particularly vulnerable to such diseases, leading to an increased demand for innovative medical devices that can provide temporary support without permanent implants. Furthermore, advancements in biodegradable materials have enhanced the performance and reliability of these stents, making them increasingly attractive to healthcare providers and patients alike. Regulatory approvals for novel biodegradable stents have also accelerated their market penetration, allowing companies to reach a broader audience. Additionally, the growing focus on personalized medicine and tailored treatment approaches is driving the development of customized biodegradable stents that align with individual patient needs. These combined factors are fostering a robust growth environment for the biodegradable stents market.

Key Highlights of the Market

• The biodegradable stents market is projected to reach USD 3.2 billion by 2035.
• North America is expected to dominate the market, accounting for over 40% of the global share by 2035.
• The coronary artery stents segment is anticipated to witness significant growth, driven by high prevalence rates of coronary artery disease.
• Innovations in stent technologies are improving the efficacy and safety profiles of biodegradable stents.
• Increasing investments in research and development by key players are expected to foster market growth.

By Product Type

Coronary Artery Stents :

Coronary artery stents are one of the most significant segments within the biodegradable stents market, primarily used to treat coronary artery disease (CAD). The increasing incidence of CAD, driven by lifestyle changes, unhealthy diets, and rising obesity rates, is fueling the demand for these stents. Biodegradable coronary artery stents are designed to provide temporary support to the artery and gradually dissolve, reducing the risk of long-term complications associated with permanent stents. Their ability to maintain blood flow during the healing process while minimizing the risk of restenosis makes them an attractive option for clinicians. Additionally, innovations in drug-eluting biodegradable stents that release medication directly at the site of intervention are enhancing patient outcomes, which is further driving market growth in this segment.

Peripheral Artery Stents :

Peripheral artery stents are designed to treat narrowing or blockages in peripheral arteries, particularly in the legs. The rising prevalence of peripheral artery disease (PAD), often associated with diabetes and a sedentary lifestyle, has led to an increased focus on developing effective treatment options. Biodegradable peripheral artery stents are advantageous as they support the artery during the healing phase and subsequently dissolve, thereby eliminating the need for long-term follow-up and reducing the risk of complications such as thrombosis. The advancements in stent design and materials have improved the flexibility and deliverability of these devices, making them easier to implant in challenging anatomical locations. Furthermore, ongoing clinical trials are exploring the efficacy of biodegradable stents in delivering drugs to enhance healing, positioning this segment for significant growth.

Esophageal Stents :

Esophageal stents are utilized primarily in patients with esophageal strictures or malignancies to maintain patency and facilitate swallowing. The increasing incidence of esophageal cancer and other gastrointestinal disorders is driving the adoption of biodegradable esophageal stents, as they provide a temporary solution with reduced long-term risks. These stents are designed to dissolve over time, alleviating the need for surgical removal and minimizing the potential for complications associated with permanent stents. The development of new biodegradable materials that are biocompatible and have enhanced mechanical properties is expected to contribute to the growth of this segment. Additionally, the ability to deliver therapeutic agents through biodegradable esophageal stents is being explored, which may further enhance their clinical applications and market potential.

Biliary Stents :

Biliary stents are employed to treat obstructions in the bile duct, often due to conditions such as gallstones or tumors. The demand for biodegradable biliary stents is increasing as they offer a novel solution that can support the bile duct during the healing process and then be absorbed by the body. The rising prevalence of cholangiocarcinoma and other biliary disorders necessitates effective treatment options that are minimally invasive and reduce the risk of complications. Biodegradable biliary stents are particularly beneficial for patients who may require subsequent interventions; their temporary nature avoids the challenges associated with long-term stent placement, such as migration or clogging. Ongoing research into improving the design and functionality of these stents is expected to enhance their adoption in clinical settings.

Ureteral Stents :

Ureteral stents are crucial for maintaining urinary flow in patients with urinary obstructions or kidney stones. The biodegradable ureteral stents segment is gaining traction as these devices provide a temporary solution to maintain patency without the need for surgical removal. The increasing incidence of kidney stones and urinary tract disorders is driving the demand for innovative ureteral stenting solutions. Biodegradable materials used in these stents enhance patient comfort and reduce the risk of infections and other complications associated with traditional metal stents. Furthermore, advancements in ureteral stent technology, including improved flexibility and biocompatibility, play a crucial role in optimizing patient outcomes. The continuous evolution of ureteral stent designs is anticipated to contribute positively to the growth of this market segment.

By Application

Coronary Artery Disease :

Coronary artery disease (CAD) is a leading application area for biodegradable stents, as this condition significantly affects millions of individuals worldwide. The rising prevalence of CAD is primarily associated with lifestyle factors, including poor diet, lack of exercise, and smoking. Biodegradable stents offer a promising solution by providing temporary support to the coronary arteries during the healing process and then dissolving, thus minimizing the risk of late stent thrombosis commonly associated with traditional metal stents. Their innovative design can also be engineered to deliver drugs that help prevent restenosis, making them particularly appealing to healthcare providers. As awareness about the advantages of biodegradable solutions continues to grow, the demand for these stents in treating CAD is expected to rise, further driving market growth in this application segment.

Peripheral Artery Disease :

Peripheral artery disease (PAD) has emerged as a significant application area for biodegradable stents, particularly due to the increasing prevalence of risk factors such as diabetes and obesity. Patients suffering from PAD often face debilitating symptoms that can severely impact their quality of life. Biodegradable peripheral artery stents provide a temporary solution that maintains blood flow and supports the affected arteries while allowing for the natural healing process to occur. The gradual dissolution of these stents eliminates the risks associated with permanent stent placement, such as complications from long-term foreign body presence. As the medical community shifts towards less invasive treatment options, the biodegradable stents market in the context of PAD is set to experience notable growth, driven by advancements in stent technology.

Gastrointestinal Disorders :

Gastrointestinal disorders, which include conditions affecting the esophagus and biliary system, are a critical application area for biodegradable stents. The use of biodegradable esophageal stents offers a significant advantage in treating strictures or obstructions, as they provide temporary support and reduce the need for surgical interventions. The increasing incidence of esophageal cancer and other gastrointestinal conditions necessitates innovative solutions that enhance patient care. Biodegradable biliary stents also play a vital role in managing obstructions in the bile duct, providing a solution that can dissolve over time, thus mitigating risks associated with permanent stenting. The growing recognition of the benefits offered by biodegradable stents in gastrointestinal applications is anticipated to drive substantial market growth in this segment.

Urological Disorders :

The treatment of urological disorders is another prominent application area for biodegradable stents. Conditions such as urinary obstructions or kidney stones can significantly impact patient health and require effective interventions. Biodegradable ureteral stents are particularly beneficial as they provide temporary support without requiring surgical removal, reducing the burden on patients. The increasing prevalence of urological disorders is driving the demand for innovative stenting solutions that enhance patient comfort and minimize complications. As advancements in stent technology continue to evolve, the biodegradable stents market is expected to see a notable increase in utilization for urological applications. Their ability to dissolve naturally within the body offers a significant advantage in managing urinary tract conditions.

By Distribution Channel

Hospitals :

Hospitals represent a key distribution channel for biodegradable stents, catering to a wide range of patient needs across various departments, including cardiology, urology, and gastroenterology. The growing number of surgical procedures performed in hospitals, combined with the increasing prevalence of chronic diseases, is driving the demand for advanced stenting solutions. Hospitals are becoming the preferred setting for the introduction of biodegradable stents due to their ability to offer a comprehensive range of medical services and postoperative care. Additionally, the availability of specialized teams of healthcare professionals in hospitals ensures better patient management and improved outcomes. As hospitals continue to adopt innovative medical technologies, the biodegradable stents segment is expected to witness robust growth through this distribution channel.

Cardiology Clinics :

Cardiology clinics are vital distribution channels for biodegradable stents, focusing specifically on the treatment of cardiovascular diseases. The increasing number of patients seeking specialized care in these clinics is accelerating the demand for minimally invasive stenting options. Biodegradable stents are gaining traction in cardiology clinics due to their ability to provide effective treatment for coronary artery disease while minimizing long-term complications. The clinics' emphasis on patient-centered care and personalized treatment plans further enhances the attractiveness of biodegradable solutions. As more cardiology clinics incorporate advanced technologies into their practice, the market for biodegradable stents is expected to expand significantly within this channel.

Ambulatory Surgical Centers :

Ambulatory surgical centers (ASCs) are increasingly becoming important distribution channels for biodegradable stents, primarily due to their focus on outpatient procedures. The efficiency of ASCs in performing minimally invasive surgeries has made them a preferred choice for many patients. Biodegradable stents are well-suited for use in ASCs, as they often require shorter recovery times and can be part of outpatient treatment regimens. The rise in patient awareness regarding the benefits of outpatient procedures, including reduced hospital stays and lower costs, is driving the adoption of biodegradable stents in ASCs. As the landscape of surgical care evolves, the growth potential for biodegradable stents in this distribution channel remains promising.

By Material Type

Polymer-Based Stents :

Polymer-based biodegradable stents are a significant segment within the biodegradable stents market due to their versatility and customization capabilities. These stents are manufactured using various biocompatible polymers that can be tailored to meet specific mechanical and degradation properties. The advantage of polymer-based stents lies in their ability to support arteries during the healing process while gradually dissolving. This feature minimizes the risk of complications associated with permanent implants and allows for the natural restoration of blood flow. The ongoing development of advanced polymer materials is enhancing the performance of these stents, making them increasingly popular among healthcare providers and patients alike. The growth of the polymer-based stent segment is expected to be driven by continuous innovation and research in material science.

Metal-Based Stents :

Metal-based biodegradable stents, while traditionally used, are increasingly being designed with biodegradable materials that combine the structural integrity of metal with the biocompatibility of polymers. These stents offer a compelling alternative for patients who require temporary support in applications such as coronary and peripheral artery interventions. Biodegradable metal stents provide the necessary strength and flexibility while gradually dissolving, thus reducing the risk of chronic complications. The advancements in metal alloys and coatings are enhancing the efficacy of metal-based biodegradable stents, positioning them for growth in the market. As the demand for hybrid solutions continues to rise, this segment is likely to witness significant innovation and expansion.

Composite-Based Stents :

Composite-based biodegradable stents are an innovative combination of various materials, including polymers and metals, that aim to optimize performance and biocompatibility. This segment is gaining traction due to its potential to provide superior mechanical properties while maintaining the advantages of biodegradability. Composite stents are designed to support the arterial structure during the critical healing phase, and their unique formulation allows for controlled degradation rates tailored to specific applications. The versatility of composite materials in stent design is driving research and development efforts, with a focus on enhancing patient outcomes and reducing complications. As clinicians increasingly seek advanced stenting solutions, the composite-based stents segment is expected to experience considerable growth.

Natural Biodegradable Stents :

Natural biodegradable stents are derived from biopolymers sourced from natural materials, offering a more organic approach to vascular interventions. These stents are designed to provide temporary support while gradually dissolving, thereby minimizing the risk of adverse reactions often associated with synthetic materials. The demand for natural biodegradable stents is growing as healthcare providers and patients alike become more conscious of the benefits of biocompatibility. The development of natural stents is accompanied by increased research into extracting and refining materials that can offer both strength and biodegradability. As the market for environmentally friendly medical devices continues to expand, natural biodegradable stents are anticipated to see increased adoption across various applications.

By Region

The regional analysis of the biodegradable stents market reveals that North America holds a dominant position, accounting for over 40% of the global market share. This dominance is attributed to the high prevalence of cardiovascular diseases, a well-established healthcare infrastructure, and significant investments in research and development. The region's strong adoption of advanced medical technologies and an increasing number of clinical studies focused on biodegradable solutions are further propelling market growth. Additionally, the rising awareness regarding the advantages of biodegradable stents among healthcare professionals and patients is expected to sustain North America's leadership in the market over the forecast period, with a CAGR of around 13% during 2025-2035.

Europe follows North America as a significant market for biodegradable stents, driven by the increasing prevalence of chronic diseases and advancements in medical technology. Countries such as Germany, France, and the United Kingdom are at the forefront of adopting biodegradable stenting solutions due to their innovative healthcare systems and emphasis on patient-centered care. The growing collaboration between medical device manufacturers and healthcare providers in Europe is fostering the development of advanced biodegradable stents tailored to meet the specific needs of patients. The European market is projected to witness steady growth, contributing to the overall expansion of the global biodegradable stents market.

Opportunities

The biodegradable stents market is ripe with opportunities, particularly as healthcare systems globally shift towards patient-centric care models that prioritize safety and reduced complications. One significant opportunity lies in the ongoing advancements in materials science and biocompatibility, which are leading to the development of innovative biodegradable stent designs. As researchers continue to explore new polymers and composites that can enhance the performance and safety profiles of biodegradable stents, there is potential for companies to develop next-generation products that meet the evolving needs of healthcare providers. Additionally, the increasing acceptance of biodegradable stents among clinicians and patients presents an opportunity for manufacturers to expand their market presence through targeted marketing and educational initiatives that highlight the benefits of these advanced solutions.

Moreover, the expansion of healthcare access in emerging economies presents a substantial opportunity for the biodegradable stents market. As countries in Asia Pacific, Latin America, and the Middle East invest in improving healthcare infrastructure, the demand for advanced medical devices, including biodegradable stents, is expected to grow. The rising awareness of cardiovascular diseases and the increasing number of interventional procedures in these regions create a favorable environment for market growth. Companies that strategically enter these emerging markets, adapt their products to local needs, and establish partnerships with healthcare providers can capitalize on this expanding market and enhance their competitive advantage.

Threats

Despite the promising outlook for the biodegradable stents market, several threats could hinder growth. One of the primary concerns is the rapid pace of technological advancements in stent manufacturing, which could lead to market saturation or increased competition as new entrants emerge. Established companies may find it challenging to maintain their market share in the face of innovative alternatives and pricing pressures. Furthermore, the rigorous regulatory environment surrounding medical devices poses challenges for manufacturers seeking to bring new biodegradable stent products to market. The lengthy approval processes and high costs associated with clinical trials may deter smaller companies from entering the market, potentially stifling innovation. Additionally, the rising prevalence of alternative treatment options, including drug-eluting stents and surgical interventions, could limit the growth potential of biodegradable stents.

Another significant restraining factor is the variability in patient response to biodegradable stents. While these devices are designed to provide temporary support, individual differences in healing and tissue response can lead to unpredictable outcomes. Concerns regarding potential complications, such as restenosis or stent thrombosis, may cause hesitation among healthcare providers when recommending biodegradable stents over traditional options. As the market evolves, addressing these concerns through robust clinical evidence and ongoing research will be essential to overcoming these threats and ensuring the continued acceptance and growth of biodegradable stents in clinical practice.

Competitor Outlook

• Abbott Laboratories
• Biosensors International Group, Ltd.
• Medtronic plc
• Boston Scientific Corporation
• Biotronik SE & Co. KG
• Cook Medical
• Cardinal Health, Inc.
• Terumo Corporation
• Janssen Pharmaceuticals, Inc.
• W. L. Gore & Associates, Inc.
• REVA Medical, Inc.
• Endologix, Inc.
• Merit Medical Systems, Inc.
• iVascular
• Stentys S.A.

The competitive landscape of the biodegradable stents market is characterized by the presence of several key players, each striving to innovate and enhance their product offerings. Established companies such as Abbott Laboratories and Boston Scientific Corporation are leading the way by investing heavily in research and development to create advanced biodegradable stents that address the unmet needs in cardiovascular and urological therapies. These companies leverage their extensive experience in the medical device industry to develop cutting-edge technologies that improve patient outcomes and expand their market reach. Additionally, strategic collaborations and partnerships among manufacturers, healthcare providers, and research institutions are common strategies employed to stay ahead in this competitive landscape.

Emerging companies, such as REVA Medical and iVascular, are also making strides in the biodegradable stents market by focusing on niche applications and offering innovative solutions that cater to specific patient populations. These companies often adopt agile business models, allowing them to respond quickly to market trends and consumer demands. Furthermore, the growing trend of personalized medicine and tailored treatment approaches is prompting new entrants to develop customized biodegradable stents that align with individual patient needs. As the market continues to evolve, the competitive dynamics will likely shift, with both established players and new entrants vying for market share through enhanced product offerings and strategic positioning.

In summary, the biodegradable stents market is witnessing significant competition as companies seek to capitalize on the growing demand for effective and safe medical solutions. The landscape is characterized by continuous innovation, with key players investing in research and development to enhance stent designs and materials. Abbott Laboratories and Medtronic are at the forefront, leveraging their established expertise in the medical device industry, while emerging players are focusing on niche applications and innovative solutions. The future of this market will depend on the ability of companies to navigate regulatory challenges, invest in R&D, and effectively address the evolving needs of healthcare providers and patients alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 iVascular
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Cook Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Stentys S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Medtronic plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Endologix, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 REVA Medical, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Terumo Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Biotronik SE & Co. KG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Cardinal Health, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Merit Medical Systems, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Janssen Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 W. L. Gore & Associates, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Biosensors International Group, Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biodegradable Stents Market, By Application
    • 6.1.1 Coronary Artery Disease
    • 6.1.2 Peripheral Artery Disease
    • 6.1.3 Gastrointestinal Disorders
    • 6.1.4 Urological Disorders
    • 6.1.5 Others
  • 6.2 Biodegradable Stents Market, By Product Type
    • 6.2.1 Coronary Artery Stents
    • 6.2.2 Peripheral Artery Stents
    • 6.2.3 Esophageal Stents
    • 6.2.4 Biliary Stents
    • 6.2.5 Ureteral Stents
  • 6.3 Biodegradable Stents Market, By Material Type
    • 6.3.1 Polymer-Based Stents
    • 6.3.2 Metal-Based Stents
    • 6.3.3 Composite-Based Stents
    • 6.3.4 Natural Biodegradable Stents
    • 6.3.5 Others
  • 6.4 Biodegradable Stents Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Cardiology Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Biodegradable Stents Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biodegradable Stents market is categorized based on

By Product Type

• Coronary Artery Stents
• Peripheral Artery Stents
• Esophageal Stents
• Biliary Stents
• Ureteral Stents

By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Gastrointestinal Disorders
• Urological Disorders
• Others

By Distribution Channel

• Hospitals
• Cardiology Clinics
• Ambulatory Surgical Centers
• Others

By Material Type

• Polymer-Based Stents
• Metal-Based Stents
• Composite-Based Stents
• Natural Biodegradable Stents
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Biosensors International Group, Ltd.
• Medtronic plc
• Boston Scientific Corporation
• Biotronik SE & Co. KG
• Cook Medical
• Cardinal Health, Inc.
• Terumo Corporation
• Janssen Pharmaceuticals, Inc.
• W. L. Gore & Associates, Inc.
• REVA Medical, Inc.
• Endologix, Inc.
• Merit Medical Systems, Inc.
• iVascular
• Stentys S.A.